Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-509 for Stem-Cell-Mobilization in Diabetic Neuropathy
NCT00665145Phase 2Completed
- Sponsor
- Sangamo Therapeutics
- Start
- Jan 2008
- Primary completion
- Oct 2009
- Modality
- Gene Silencing, Plasmid DNA, Zinc Finger Nucleases
- Countries
- 1
01
Overview
A Phase 2 trial of SB-509 in diabetic neuropathy, sponsored by Sangamo Therapeutics. Started Jan 2008; status: completed.
02
Drugs
SB-509
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT00665145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665145.